Physician profile
Lon E Katz
NPI 1992792212
$3,349.47
in general payments reported to CMS, 2019-2025
33 companies · $448 in 2025
The $448 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $252 · 2021: $612 · 2022: $461 · 2023: $602 · 2024: $543 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $447.01 | 2020-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $404.49 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $365.60 | 2019-2025 | |
| Hologic Sales and Service, LLC | $318.52 | 2021-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $256.39 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $191.24 | 2021-2024 | |
| Medtronic, INC. | $159.65 | 2025 | Truclear |
| Exeltis, USA INC. | $141.41 | 2021-2025 | Slynd |
| Axonics, INC. | $110.52 | 2024 | Bulkamid |
| Evofem Biosciences, INC. | $103.67 | 2021-2022 | |
| Gynesonics, INC. | $88.69 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Myovant Sciences INC. | $83.52 | 2021 | |
| Daiichi Sankyo INC. | $66.57 | 2019-2022 | |
| Therapeuticsmd, INC. | $64.46 | 2019-2022 | |
| Amgen INC. | $62.55 | 2019-2025 | Evenity |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $54.34 | 2024-2025 | Nexplanon |
| Aspira Women'S Health INC | $52.49 | 2022 | |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Lupin INC. | $39.36 | 2019-2020 | |
| Sage Therapeutics, LLC | $35.54 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $34.97 | 2020-2021 | |
| Channel Medsystems, INC. | $33.17 | 2025 | |
| Scynexis, INC. | $29.75 | 2022 | |
| Smith+Nephew, INC. | $25.57 | 2025 | Pico 7 |
| Allergan, INC. | $25.01 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.15 | 2019 | |
| Minerva Surgical, INC | $21.28 | 2020 | |
| Vertical Pharmaceuticals, LLC | $18.29 | 2019 | |
| Abbott Laboratories | $14.11 | 2023 | Proclaim |
| Supernus Pharmaceuticals, INC. | $13.84 | 2025 | Qelbree |
| Shield Therapeutics INC | $13.54 | 2022 | |
| Mission Pharmacal Company | $11.77 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lon Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.